Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials.
Stride velocity 95 th Centile_Insights into gaining regulatory qualification of the first wearable derived digital endpoint for use in Duchenne Muscular Dystrophy trials.pdf
Biomarkers; clinical trial; drug approval; drug development; gait; gait analysis; motor activity; movement; neuromuscular diseases; walking; wearable electronic devices
Abstract :
[en] In 2019, stride velocity 95th centile (SV95C) became the first wearable-derived digital clinical outcome assessment (COA) qualified by the European Medicines Agency (EMA) for use as a secondary endpoint in trials for Duchenne muscular dystrophy. SV95C was approved via the EMA's qualification pathway for novel methodologies for medicine development, which is a voluntary procedure for assessing the regulatory acceptability of innovative methods used in pharmaceutical research and development. SV95C is an objective, real-world digital ambulation measure of peak performance, representing the speed of the fastest strides taken by the wearer over a recording period of 180 hours. SV95C is correlated with traditional clinic-based assessments of motor function and has greater sensitivity to clinical change over 6 months than other wearable-derived stride variables, for example, median stride length or velocity. SV95C overcomes many limitations of episodic, clinic-based motor function testing, allowing the assessment of ambulation ability between clinic visits and under free-living conditions. Here we highlight considerations and challenges in developing SV95C using evidence generated by a high-performance wearable sensor. We also provide a commentary of the device's technical capabilities, which were a determining factor in the regulatory approval of SV95C. This article aims to provide insights into the methods employed, and the challenges faced, during the regulatory approval process for researchers developing new digital tools for patients with diseases that affect motor function.
Disciplines :
Pediatrics Neurology
Author, co-author :
Servais, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > Département de Pédiatrie > Service de pédiatrie
Yen, Karl
Guridi, Maitea
Lukawy, Jacek
Vissière, David
Strijbos, Paul
Language :
English
Title :
Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Alfano L, Lowes L, Berry K, Flanigan K, Cripe L, Mendell J. Role of motivation on performance of the 6-minute walk test in boys with Duchenne muscular dystrophy. Dev Med Child Neurol. 2015;57(S5):57-8.
Prahm KP,Witting N,Vissing J. Decreased variability of the 6-minute walk test by heart rate correction in patients with neuromuscular disease. PloS One. 2014;9(12):e114273.
Grages SM, Bell M, Berlau DJ. New and emerging pharmacotherapy for duchenne muscular dystrophy: A focus on synthetic therapeutics. Expert Opin Pharmacother. 2020; 21(7):841-51.
Dobkin BH, Dorsch A. The promise of mHealth: Daily activity monitoring and outcome assessments by wearable sensors. Neurorehabil Neural Repair. 2011;25(9):788-98.
US Food and Drug Administration. The long run is now: How FDA is advancing digital tools for medical product development. (2018) Available at: Https://www.fda.gov/news-events/speeches-fda-officials/long-run-now-how-fda-advancing-digital-tools-medical-product-development-10 252018. (Accessed October 25, 2020).
European Medicines Agency. Regulatory Science to 2025 Reference material. (2018) Available at: Https://www.ema. europa.eu/en/documents/other/reference-material-multista keholder-workshop-launch-consultation-european-medici nes-agency-ema-human en.pdf. (Accessed October 25, 2021).
Statista. Connected wearable devices worldwide 2016-2021. (2018) Available at: Https://www.statista.com/statis tics/487291/global-connected-wearable-devices/. (Accessed October 25, 2021).
Fowler EG, Staudt LA, Heberer KR, Sienko SE, Buckon CE, Bagley AM, et al. Longitudinal community walking activity in Duchenne muscular dystrophy. Muscle & Nerve. 2018;57(3):401-6.
McDonald CM, Widman LM, Walsh DD, Walsh SA, Abresch RT. Use of step activity monitoring for continuous physical activity assessment in boys with Duchenne muscular dystrophy. Archives of Physical Medicine and Rehabilitation. 2005;86(4):802-8.
Izmailova ES, Wagner JA, Perakslis ED. Wearable devices in clinical trials: Hype and hypothesis. Clin Pharmacol Ther. 2018;104(1):42-52.
Hobart JC, Lamping DL, Thompson AJ. Evaluating neurological outcome measures: The bare essentials. J Neurol Neurosurg Psychiatry. 1996;60(2):127-30.
Louie C, D'Agostino EN, Han D, Ryken TC. Determining an appropriate outcome measure in neurosurgical research: Investigating meaningful, valid, and practical metrics. Cureus. 2019;11(9):e5610.
European Medicines Agency. Qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne muscular dystrophy measured by a valid and suitable wearable device. (2019) Available at: Https://www. ema.europa.eu/en/documents/scientific-guideline/quali fication-opinion-stride-velocity-95th-centile-secondaryendpoint-duchenne-muscular-dystrophy en.pdf. (Accessed October 25, 2021).
US Food and Drug Administration. Clinical Outcome Assessments (COA) Qualification Program. Letter of Intent: ActiMyo.Available at: Https://www.fda.gov/media/119254/download. (Accessed October 25, 2021).
Lilien C, Gasnier E, GidaroT, Seferian A, Grelet M,Vissière D, et al. Home-based monitor for gait and activity analysis. J Vis Exp. 2019(150).
Institute of Myology. ActiMyo. Available at: Https://www. institut-myologie.org/imotion/actimyo/lang=en. (Accessed October 25, 2021).
Servais L, Camino E, Clement A, McDonald CM, Lukawy J, Lowes LP, et al. First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases. Digital Biomarkers. 2021;5(2):183-90.
Haberkamp M, Moseley J, Athanasiou D, de Andres-Trelles F, Elferink A, Rosa MM, et al. European regulators' views on a wearable-derived performance measurement of Ambulation for Duchenne muscular dystrophy regulatory trials. Neuromuscul Disord. 2019;29(7):514-6.
Goudriaan M, Van den Hauwe M, Dekeerle J, Verhelst L, Molenaers G, Goemans N, et al. Gait deviations in Duchenne muscular dystrophy-Part 1. A systematic review. Gait & posture. 2018;62:247-61.
McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013;48(3):357-68.
Chabanon A, Seferian AM, Daron A, Pereon Y, Cances C, Vuillerot C, et al. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. PLoS One. 2018;13(7):e0201004.
Annoussamy M, Seferian AM, Daron A, Pereon Y, Cances C, Vuillerot C, et al. Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol. 2021;8(8):359-73.
Morales Mestre N, Audag N, Caty G, Reychler G. Learning and encouragement effects on six-minute walking test in children. J Pediatr. 2018;198:98-103.
Reilmann R, Schubert R. Chapter 18-Motor outcome measures in Huntington disease clinical trials. In: Feigin AS, Anderson KE, editors. Handbook of Clinical Neurology. 144: Elsevier; 2017. pp. 209-25.
Dorsey ER, Papapetropoulos S, Xiong M, Kieburtz K. The first frontier: Digital biomarkers for neurodegenerative disorders. Digital Biomarkers. 2017;1(1):6-13.
European Medicines Agency. Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy. (2015)Available at: Https://www.ema.europa.eu/en/documents/scientificguideline/guideline-clinical-investigation-medicinalproducts-treatment-duchenne-becker-musculardystrophy en.pdf. (Accessed October 25, 2021).
Seferian AM, Moraux A, Canal A, Decostre V, Diebate O, Le Moing AG, et al. Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: An observational multicenter trial. PLoS One. 2015;10(4):e0121799.
Seferian AM, Moraux A, Annoussamy M, Canal A, Decostre V, Diebate O, et al. Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: An observational multicenter trial. PLoS One. 2015;10(2):e0113999.
Hogrel J-Y, Decostre V, Ledoux I, de Antonio M, Niks EH, de Groot I, et al. Normalized grip strength is a sensitive outcome measure through all stages of Duchenne muscular dystrophy. J Neurol. 2020;267(7):2022-8.
Bushby K, Finkel R,Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477-87.
McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): A multicentre, randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2017;390(10101):1489-98.
Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637-47.
Aartsma-Rus A, Krieg AM. FDA approves eteplirsen for Duchenne muscular dystrophy: The next chapter in the eteplirsen saga. Nucleic Acid Ther. 2017;27(1):1-3.
European Medicines Agency. Assessment report for Kyndrisa. (2016) Available at: Https://www.ema.europa.eu/documents/withdrawal-report/withdrawal-assessment-repo rt-kyndrisa en.pdf. (Accessed October 25, 2021).
Goemans N, Mercuri E, Belousova E, Komaki H, Dubrovsky A, McDonald CM, et al. A randomized placebocontrolled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscul Disord. 2018;28(1):4-15.
Iff J, Gerrits C, Sajeev G, Signorovitch J, Tuttle E, Birk E, et al. Eteplirsen delays time to loss of ambulation in patients with Duchenne muscular dystrophy compared with patients receiving standard of care. Muscular Dystrophy Association Clinical and Scientific Conference; 13-17 April 2019; Orlando, USA.
Charleston JS, Schnell FJ, Dworzak J, Donoghue C, Lewis S, Chen L, et al. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production. Neurology. 2018;90(24):e2146-e54.
Delage A, Bucella F, Desguerre I, Muntoni F, Osorio AN, Tulinius M, et al. Effect of Ataluren on Age at Loss of Ambulation in Nonsense Mutation Duchenne Muscular Dystrophy: Observational Data from the STRIDE Registry (P1.6-067). Neurology. 2019;92(15 Supplement):P1.6-067.
New drug assessment of drisapersen for Duchenne Muscular Dystrophy. US Food and Drug Administration Available at: Https://www.fda.gov/media/95912/download.(2015). (Accessed October 25, 2021).
US Food and Drug Administration. New drug assessment of eteplirsen for Duchenne Muscular Dystrophy (redacted). Available at: Https://www.accessdata.fda.gov/drugsatfda docs/nda/2016/206488Orig1s000SumR.pdf.(2016). (Accessed October 25, 2021).
US Food and Drug Administration. Newdrug assessment of ataluren for Duchenne Muscular Dystrophy. (2017) Available at: Https://www.fda.gov/media/109528/download. (Accessed October 25, 2021).
European Medicines Agency. Translarna. Available at: Https://www.ema.europa.eu/en/documents/procedural-step s-after/translarna-epar-procedural-steps-taken-scientific-in formation-after-authorisation en.pdf. (Accessed October 25, 2021).
US Food and Drug Administration. New drug application. Ataluren. (2017) Available at: Https://www.fda.gov/do wnloads/advisorycommittees/committeesmeetingmateri als/drugs/peripheralandcentralnervoussystemdrugsadvisory committee/ucm577349.pdf. (Accessed October 25, 2021).
Aartsma-Rus A, Krieg A, Goemans N. A sequel to the eteplirsen saga: Eteplirsen is approved in the United States but was not approved in Europe. Nucleic Acid Ther. 2018; 29(1):13-5.
Hilhorst N, Spanoudi-Kitrimi I, Goemans N, Morren MA. Injection site reactions after long-term subcutaneous delivery of drisapersen: A retrospective study. Eur J Pediatr. 2019;178(2):253-8.
Pane M, Mazzone ES, Sivo S, Sormani MP, Messina SD, Amico A, et al. LongTerm Natural History Data inAmbulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes. PLOS ONE. 2014;9(10):e108205.
Goemans N, vanden Hauwe M, Signorovitch J, Swallow E, Song J, Collaborative Trajectory Analysis P. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. PLOS ONE. 2016;11(10):e0164684.
Doglio L, Pavan E, Pernigotti I, Petralia P, Frigo C, Minetti C. Early signs of gait deviation in Duchenne muscular dystrophy. Eur J Phys Rehabil Med. 2011;47(4):587-94.
European Medicines Agency. Questions and answers: Qualification of digital technology-based methodologies to support approval of medicinal products. (2020)Available at: Https://www.ema.europa.eu/en/documents/other/questionsanswers-qualification-digital-technology-based-methodol ogies-support-approval-medicinal en.pdf (Accessed October 25, 2021).
Aydemir GA, SaranlA. Characterization and calibration of MEMS inertial sensors for state and parameter estimation applications. Measurement. 2012;45(5):1210-25.
Cereatti A, Trojaniello D, Della Croce U. Accurately measuring human movement using magneto-inertial sensors: Techniques and challenges. 2015 IEEE International Symposium on Inertial Sensors and Systems (ISISS) Proceedings. 2015:1-4.
Attal F, Mohammed S, Dedabrishvili M, Chamroukhi F, Oukhellou L, Amirat Y. Physical Human Activity Recognition UsingWearable Sensors. Sensors (Basel). 2015;15(12): 31314-38.
Caldas R, Mundt M, Potthast W, de Lima Neto FB, Markert B. A systematic review of gait analysis methods based on inertial sensors and adaptive algorithms. Gait Posture. 2017;57:204-10.
Yang S, Li Q. Inertial sensor-based methods in walking speed estimation: A systematic review. Sensors (Basel). 2012;12(5):6102-16.
Vienne A, Barrois RP, Buffat S, Ricard D,Vidal P-P. Inertial sensors to assess gait quality in patients with neurological disorders: A systematic review of technical and analytical challenges. Front Psychol. 2017;8:817.
Beaufils B, Chazal F, Grelet M, Michel B. Robust stride detector from ankle-mounted inertial sensors for pedestrian navigation and activity recognition with machine learning approaches. Sensors (Basel). 2019;19(20):4491.
Takeda R, Lisco G, Fujisawa T, Gastaldi L, Tohyama H, Tadano S. Drift Removal for Improving the Accuracy of Gait Parameters Using Wearable Sensor Systems. Sensors. 2014;14(12):23230-47.
Ahmadi A, Destelle F, Unzueta L, Monaghan DS, Linaza MT, Moran K, et al. 3D human gait reconstruction and monitoring using body-worn inertial sensors and kinematic modeling. IEEE Sens J. 2016;16(24):8823-31.
Ilyas M, Cho K, Baeg S-H, Park S. Drift reduction in pedestrian navigation system by exploiting motion constraints and magnetic field. Sensors (Basel). 2016;16(9): 1455.
Shiau JK, Ma DM, Huang CX, Chang MY. MEMS gyroscope null drift and compensation based on neural network. Advanced Materials Research. 2011;255:2077-81.
Vissiere D, Hillion M, Dorveaux E, Augustin J, Grelet M, inventors; SYSNAV, assignee. Method for estimating the movement of a pedestrian. United States patent US20180292230A1. 2019-01-25.
Le Moing AG, Seferian AM, Moraux A, Annoussamy M, Dorveaux E, Gasnier E, et al. A movement monitor based on magneto-inertial sensors for non-ambulant patients with Duchenne muscular dystrophy: A pilot study in controlled environment. PLoS One. 2016;11(6):e0156696.
Jimenez-Moreno AC, Newman J, Charman SJ, Catt M, Trenell MI, Gorman GS, et al. Measuring habitual physical activity in neuromuscular disorders: A systematic review. J Neuromuscul Dis. 2017;4:25-52.
Elsworth C, Dawes H, Winward C, Howells K, Collett J, Dennis A, et al. Pedometer step counts in individuals with neurological conditions. Clin Rehabil. 2009;23(2):171-5.
Poleur M, Ulinici A, Daron A, Schneider O, Farra FD, Demonceau M, et al. Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment. Orphanet J Rare Dis. 2021; 16(1):318.
Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, et al. Corticosteroids in Duchenne muscular dystrophy: Major variations in practice. Muscle Nerve. 2013;48(1): 27-31.
Servais L, Gidaro T, Seferian A, Gasnier E, Daron A, Ulinici A, et al. P. 191Maximal stride velocity detects positive and negative changes over 6-month-time period in ambulant patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2019;29:S105.
Neely JG, Karni RJ, Engel SH, Fraley PL, Nussenbaum B, Paniello RC. Practical guides to understanding sample size and minimal clinically important difference (MCID). Otolaryngol Head Neck Surg. 2007;136(1):14-8.
Emery AEH. Population frequencies of inherited neuromuscular diseases-A world survey. Neuromuscul Disord. 1991;1(1):19-29.
El Mouelhi M. Drug development and challenges for neuromuscular clinical trials. J Mol Neurosci. 2016;58(3): 374-8.
Schaefer SE, Van Loan M, German JB. A feasibility study of wearable activity monitors for pre-adolescent school-age children. Prev Chronic Dis. 2014;11:E85.
Hermsen S, Moons J, Kerkhof P, Wiekens C, De Groot M. Determinants for Sustained Use of an Activity Tracker: Observational Study. JMIR Mhealth Uhealth. 2017;5(10): E164.
Kostkova P, Brewer H, de Lusignan S, Fottrell E, Goldacre B, Hart G, et al. Who Owns the Data Open Data for Healthcare. Front Public Health. 2016;4:7.
Gidaro T, Gasnier E, Annoussamy M, Vissing J, Attarian S, Mozaffar T, et al. Home-based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy. Muscle&Nerve.Forthcoming 2021.
Annoussamy M, Gasnier E, Baets J, Schara U, Grange A, Lilien C, et al. Feasibility and baseline values of continuous movement measurement in patients with centronuclear myopathy by using ActiMyo. Neuromuscular Disorders. 2019;29:S107.
Rubim VS, Drumond Neto C, Romeo JL, Montera MW. Prognostic value of the Six-Minute Walk Test in heart failure. Arq Bras Cardiol. 2006;86(2):120-5.
Takigawa N, Tada A, Soda R, Date H, Yamashita M, Endo S, et al. Distance and oxygen desaturation in 6-min walk test predict prognosis in COPD patients. Respir Med. 2007;101(3):561-7.
Puciato D, Borysiuk Z, Rozpara M. Quality of life and physical activity in an older working-age population. Clin Interv Aging. 2017;12:1627-34.
Kripp M, Heußer AL, Belle S, Gerhardt A, Merx K, Hofmann WK, et al. Does physical activity improve quality of life in cancer patients undergoing chemotherapy Oncol Res Treat. 2015;38(5):230-6.
Huang W, Gao K, Liu Y, Liang M, Zhang X. The adverse impact of glaucoma on psychological function and daily physical activity. J Ophthalmol. 2020;2020:9606420.
Schmal H, Holsgaard-Larsen A, Izadpanah K, Brønd JC, Madsen CF, Lauritsen J. Validation of activity tracking procedures in elderly patients after operative treatment of proximal femur fractures. Rehabil Res Pract. 2018;2018: 3521271.
Case MA, Burwick HA, Volpp KG, Patel MS. Accuracy of Smartphone Applications andWearable Devices for Tracking Physical Activity Data. JAMA. 2015;313(6):625-6.
Hildebrand M, Van Hees VT, Hansen BH, Ekelund U. Age group comparability of raw accelerometer output from wrist- A nd hip-worn monitors. Med Sci Sports Exerc. 2014;46(9):1816-24.
Straiton N, Alharbi M, Bauman A, Neubeck L, Gullick J, Bhindi R, et al. The validity and reliability of consumergrade activity trackers in older, community-dwelling adults: A systematic review. Maturitas. 2018;112:85-93.
Izmailova ES,Wagner JA, Ammour N, Amondikar N, Bell-Vlasov A, Berman S, et al. Remote Digital Monitoring for Medical Product Development. Clinical and Translational Science. 2021;14(1):94-101.
Cox SM, Lane A, Volchenboum SL. Use of Wearable, Mobile, and Sensor Technology in Cancer Clinical Trials. JCO Clinical Cancer Informatics. 2018(2):1-11.
Mobilise-D. Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement. Available at: Https://www.mobilise-d.eu/. (Accessed October 25, 2021).
Rochester L, Mazzà C, Mueller A, Caulfield B, McCarthy M, Becker C, et al. A roadmap to inform development, validation and approval of digital mobility outcomes: The Mobilise-D approach. Digital Biomarkers. 2020;4(1): 13-27.
Ricotti V, Kadirvelu B, Selby V, Voit T, Faisal A. Towards high-resolution clinical digital biomarkers for Duchenne muscular dystrophy. Neuromuscul Disord. 2019;29:S108.
Ricotti V, Kadirvelu B, Auepanwiriyakul C, Zeng S, Selby V, Voit T, et al. P. 205Daily life digital biomarkers for longitudinal monitoring of Duchenne muscular dystrophy with wearable sensors. Neuromuscular Disorders. 2019;29: S109.
Suresh Kumar V, Krishnamoorthi C. Development of electrical transduction based wearable tactile sensors for human vital signs monitor: Fundamentals, methodologies and applications. Sensors and Actuators A: Physical. 2021;321: 112582.
Guillodo E, Lemey C, Simonnet M,Walter M, Baca-Garca E, Masetti V, et al. Clinical applications of mobile health wearable-based sleep monitoring: Systematic review. JMIR mHealth and uHealth. 2020;8(4):e10733.
European Medicines Agency. Qualification of novel methodologies for drug development: Guidance to applicants. (2014) Available at: Https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualificationnovel-methodologies-drug-development-guidance-applica nts en.pdf (Accessed October 25, 2021).
Innovative Medicines Initiative. Report from the IMIEMA-FDA Regulatory Science Summit-Collaborative research through public-private partnership in support to advancing regulatory science. (2017) Available at: Https://www.imi.europa.eu/sites/default/files/uploads/documents/news-events/press-releases/RegulatorySummit2017 report .pdf. (Accessed October 25, 2021).
Innovative Medicines Initiative. Raising awareness of regulatory requirements.Aguidance tool for researchers. (2015) Available at: Https://www.imi.europa.eu/sites/default/files/uploads/documents/apply-for-funding/call-documents/imi2/RegulatoryRequirementsGuide.pdf (Accessed October 25, 2021).
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
